#USA #Boston #diabetes treatment #Morphic Medical #Terri Cooper

Morphic Medical Appoints Terri Cooper to Its Board

Morphic Medical, renowned for developing the world's first medical device aimed at tackling the root cause of type 2 diabetes, has made headlines with the recent appointment of Terri Cooper to its board of directors. This strategic move aligns with the company’s commitment to innovation in metabolic health solutions, particularly in the face of rising global diabetes rates.

A Stellar Career in Healthcare

Terri Cooper brings over 35 years of expertise in the life sciences and healthcare industry. She has established herself not just as a leader but as a key innovator across various sectors, bridging the gap between public and private domains. Her previous role as a director at Deloitte’s consulting practice for healthcare provides her with a unique vantage point on industry challenges and opportunities.

Her extensive experience spans complex organizational structures, brand development, and regulatory norms—a combination critical for any company operating in the high-stakes health sector. In her tenure at Deloitte, Terri successfully grew the life sciences research and development arm, orchestrating global organizational and financial restructurings which led to significant performance enhancements. Furthermore, she has spearheaded transformative strategies, including innovation initiatives and mergers and acquisitions, which have resulted in competitive advantage and growth opportunities.

Vision for Metabolic Health

"I am truly honored to join the board of Morphic Medical at such a pivotal time for metabolic health advancement," Terri stated. Her commitment to the company underscores Morphic Medical's dedication to offering less invasive, patient-centered solutions—an urgent need in today's healthcare landscape. She expressed her eagerness to support the team in extending access and improving outcomes for individuals grappling with obesity and type 2 diabetes.

Morphic Medical’s CEO, Mike Gutteridge, echoed this sentiment, stating, "We are thrilled to welcome Terri to our board. Her three decades of global leadership experience in life sciences and healthcare, combined with her in-depth knowledge of strategy, regulatory navigation, organizational transformation, and value creation, will be pivotal as we advance our clinical trials and enhance the foundations of our innovative RESET therapy."

Pioneering Solutions

Morphic Medical is developing RESET, an endoscopic therapy offering a non-surgical alternative for treating morbid obesity and concomitant cardiometabolic risk factors like type 2 diabetes. While RESET is currently limited to experimental use in the U.S., its potential represents a significant shift toward addressing obesity and diabetes through innovative medical technology.

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical continues to break new ground in the field of diabetes treatment. For more details about their pioneering work, visit morphicmedical.com or follow them on social media channels like Twitter and LinkedIn.